

Clinical trials of dronedarone

TrialResults-center www.trialresultscenter.org

1 heart failure

Trial	Treatments	Patients	Trials design and methods
dronedarone vs placebo			
ANDROMEDA , 2008 [NCT00543699] n=310/317 follow-up: median 2 months	dronedarone 400mg twice daily versus placebo	patients hospitalized with symptomatic heart failure and severe left ventricular systolic dysfunction	Parallel groups double blind

More details and results :

- antiarrhythmic drugs for heart failure in all type of heart failure at <http://www.trialresultscenter.org/go-Q46>

References

ANDROMEDA, 2008:

Kber L, Torp-Pedersen C, McMurray JJ, Gtzsche O, Lvy S, Crijs H, Amlie J, Carlsen J Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-87 [[18565860](#)]

2 atrial fibrillation

Trial	Treatments	Patients	Trials design and methods
dronedarone vs placebo			
PALLAS , 2011 [NCT01151137] n=1577/1572 follow-up: 3 years	Dronedarone versus placebo	patients with permanent atrial fibrillation and additional risk factors	Parallel groups double-blind
ADONIS , 2007 [NCT00259376] n=417/208 follow-up: 12 months	dronedarone 400 mg twice daily versus placebo	patients with at least one episode of atrial fibrillation in the preceding 3 months, and in sinus rhythm for at least 1 hour before randomization	Parallel groups double blind United States, Canada, Australia, South Africa, Argentina

continued...

Trial	Treatments	Patients	Trials design and methods
ATHENA , 2009 [NCT00174785] n=2301/2327 follow-up: 21.5 months	dronedarone 400 mg twice a day versus placebo	patients (>70y) with paroxysmal or persistent atrial fibrillation and additional risk factors for death	Parallel groups double blind 37 countries
DAFNE , 2003 n=151/48 follow-up:	Dronedarone various doses (800, 1200, 1600 mg/d) versus placebo	patients with Persistent AF	Parallel groups double blind
ERATO , 2008 [18760136] n=85/89 follow-up: 6 months	dronedarone 400 mg twice daily versus placebo	patients with permanent AF	Parallel groups double blind
EURIDIS , 2007 [NCT00259428] n=411/201 follow-up: 12 months	dronedarone 400 mg twice daily versus placebo	patients with at least one episode of atrial fibrillation in the preceding 3 months, and in sinus rhythm for at least 1 hour before randomization	Parallel groups double blind 12 European countries
EURIDIS ADONIS (pooled analysis) , 2009 n=828/409 follow-up: 12 months	Dronedarone 800 mg/d versus placebo	AF documented in the previous 3 months	Parallel groups double blind Europe, US, canada, Australia, South A, Argentina
dronedarone vs amiodarone			
DIONISOS , 2007 [NCT00489736] n=249/255 follow-up: 6 months	Dronedarone (400mg BID) versus Amiodarone (600mg daily for 28 days, then 200mg daily thereafter)	Patients with documented atrial fibrillation for more than 72 hours for whom cardioversion and antiarrhythmic treatment is indicated in the opinion of the investigator and under oral anticoagulation	Parallel groups double blind

More details and results :

- antiarrhythmic drugs for atrial fibrillation in maintaining sinus rhythm after cardioversion at <http://www.trialresultscenter.org/go-Q113>
- antiarrhythmic drugs for atrial fibrillation in rate control at <http://www.trialresultscenter.org/go-Q273>
- antiarrhythmic drugs for atrial fibrillation in prevention of cardiovascular events at <http://www.trialresultscenter.org/go-Q514>

References

PALLAS, 2011:

Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum A, Blomström P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacortaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosil Dronedaronone in High-Risk Permanent Atrial Fibrillation. *N Engl J Med* 2011 Nov 14;: [22082198] [10.1056/NEJMoa1109867](https://doi.org/10.1056/NEJMoa1109867)

Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum A, Blomström P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacortaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosil Dronedaronone in High-Risk Permanent Atrial Fibrillation. *N Engl J Med* 2011 Nov 14;: [22082198] [10.1056/NEJMoa1109867](https://doi.org/10.1056/NEJMoa1109867)

ADONIS, 2007:

Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH Dronedaronone for maintenance of sinus rhythm in atrial fibrillation or flutter. *N Engl J Med* 2007 Sep 6;357:987-99 [17804843]

ATHENA, 2009:

Hohnloser SH, Crijns HJ, van Eickels M, et al. The ATHENA trial: Effects of dronedarone on cardiovascular hospitalization and death in patients with atrial fibrillation or flutter. HRS) Annual Scientific Sessions; May 14-17, 2008, San Francisco

Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ Effect of dronedarone on cardiovascular events in atrial fibrillation. *N Engl J Med* 2009 Feb 12;360:668-78 [19213680]

DAFNE, 2003:

Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH Dronedaronone for prevention of atrial fibrillation: a dose-ranging study. *Eur Heart J* 2003;24:1481-7 [12919771]

ERATO, 2008:

Davy JM, Herold M, Hognlund C, Timmermans A, Alings A, Radzik D, Van Kempen L Dronedaronone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dronedaronone for the control of ventricular rate during atrial fibrillation (ERATO) study. *Am Heart J* 2008 Sep;156:527.e1-9 [18760136]

EURIDIS, 2007:

Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH Dronedaronone for maintenance of sinus rhythm in atrial fibrillation or flutter. *N Engl J Med* 2007;357:987-99 [17804843]

EURIDIS ADONIS (pooled analysis), 2009:

Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH *N Engl J Med* 2007 Sep 6;357:987-99 [17804843]

DIONISOS, 2007:

Ezekowitz MD *N Engl J Med* 2007;357:1039-41 [17804851]

Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedaronone versus amiodaronone in patients with persistent atrial fibrillation: the DIONYSOS study. *J Cardiovasc Electrophysiol* 2010;21:597-605 [20384650] [10.1111/j.1540-8167.2010.01764.x](https://doi.org/10.1111/j.1540-8167.2010.01764.x)

Entry terms: Multaq